» Articles » PMID: 18228206

Tea Polyphenols, Their Biological Effects and Potential Molecular Targets

Overview
Date 2008 Jan 30
PMID 18228206
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Tea is the most popular beverage in the world, second only to water. Tea contains an infusion of the leaves from the Camellia sinensis plant rich in polyphenolic compounds known as catechins, the most abundant of which is (-)-EGCG. Although tea has been consumed for centuries, it has only recently been studied extensively as a health-promoting beverage that may act to prevent a number of chronic diseases and cancers. The results of several investigations indicate that green tea consumption may be of modest benefit in reducing the plasma concentration of cholesterol and preventing atherosclerosis. Additionally, the cancer-preventive effects of green tea are widely supported by results from epidemiological, cell culture, animal and clinical studies. In vitro cell culture studies show that tea polyphenols potently induce apoptotic cell death and cell cycle arrest in tumor cells but not in their normal cell counterparts. Green tea polyphenols were shown to affect several biological pathways, including growth factor-mediated pathway, the mitogen-activated protein (MAP) kinase-dependent pathway, and ubiquitin/proteasome degradation pathways. Various animal studies have revealed that treatment with green tea inhibits tumor incidence and multiplicity in different organ sites such as skin, lung, liver, stomach, mammary gland and colon. Recently, phase I and II clinical trials have been conducted to explore the anticancer effects of green tea in humans. A major challenge of cancer prevention is to integrate new molecular findings into clinical practice. Therefore, identification of more molecular targets and biomarkers for tea polyphenols is essential for improving the design of green tea trials and will greatly assist in a better understanding of the mechanisms underlying its anti-cancer activity.

Citing Articles

From Spent Black and Green Tea to Potential Health Boosters: Optimization of Polyphenol Extraction and Assessment of Their Antioxidant and Antibacterial Activities.

Harfoush A, Swaidan A, Khazaal S, Sokhn E, Grimi N, Debs E Antioxidants (Basel). 2025; 13(12.

PMID: 39765915 PMC: 11673901. DOI: 10.3390/antiox13121588.


Potential Benefits of Green Tea in Prostate Cancer Prevention and Treatment: A Comprehensive Review.

Liu G, Yao Z, Chen G, Li Y, Liang B Chin J Integr Med. 2024; 30(11):1045-1055.

PMID: 38561489 DOI: 10.1007/s11655-024-4100-2.


Eat4Genes: a bioinformatic rational gene targeting app and prototype model for improving human health.

Ford M, Cooley J, Sripada V, Xu Z, Erickson J, Bennett K Front Nutr. 2023; 10:1196520.

PMID: 37305078 PMC: 10250663. DOI: 10.3389/fnut.2023.1196520.


Epigallocatechin gallate alleviates high-fat diet-induced hepatic lipotoxicity by targeting mitochondrial ROS-mediated ferroptosis.

Ding S, Chu X, Jin Y, Jiang J, Zhao X, Yu M Front Pharmacol. 2023; 14:1148814.

PMID: 37025486 PMC: 10070829. DOI: 10.3389/fphar.2023.1148814.


Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.

Ambrosio F, Costa G, Gallo Cantafio M, Torcasio R, Trapasso F, Alcaro S Molecules. 2023; 28(3).

PMID: 36771100 PMC: 9919276. DOI: 10.3390/molecules28031438.


References
1.
Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W . Proteasome from Thermoplasma acidophilum: a threonine protease. Science. 1995; 268(5210):579-82. DOI: 10.1126/science.7725107. View

2.
Mukhtar H, Ahmad N . Cancer chemoprevention: future holds in multiple agents. Toxicol Appl Pharmacol. 1999; 158(3):207-10. DOI: 10.1006/taap.1999.8721. View

3.
Vinson J, Teufel K, Wu N . Green and black teas inhibit atherosclerosis by lipid, antioxidant, and fibrinolytic mechanisms. J Agric Food Chem. 2004; 52(11):3661-5. DOI: 10.1021/jf035255l. View

4.
Surh Y . Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003; 3(10):768-80. DOI: 10.1038/nrc1189. View

5.
Kane R, Farrell A, Sridhara R, Pazdur R . United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006; 12(10):2955-60. DOI: 10.1158/1078-0432.CCR-06-0170. View